ZUG, Zwitserland–(BUSINESS WIRE)– De Zwitserse farmaceut Primex Pharmaceuticals AG maakt bekend dat Alan Knox is benoemd tot hoofd internationale marketing. Hij treedt op 1 juli 2016 toe tot Primex Pharmaceuticals’ uitvoerende bestuur.
Alan Knox werkte voor deze aanstelling voor MSD International AG als vicepresident internationale marketing. Bij MSD was hij ook verantwoordelijk voor internationale portfoliostrategieën en regionale activiteiten in de Europese Unie, Oost-Europa, het Midden-Oosten en Afrika. Voorafgaand aan zijn werk voor MSD bekleedde hij bestuursfuncties bij Sandoz en AstraZeneca.
Primex Pharmaceuticals Appoints Alan Knox as Head of Global Marketing
ZUG, Switzerland–(BUSINESS WIRE)– Swiss pharmaceutical company Primex Pharmaceuticals AG announces the appointment of Alan Knox as Head of Global Marketing. On July 1, 2016, he joins Primex Pharmaceuticals’ Executive Management Team.
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160601005092/en/
Alan Knox (Photo: Business Wire)
Most recently, Alan Knox worked for MSD International AG as VP Global Marketing. At MSD, he has also held responsibilities for Global Portfolio Strategy and Regional Operations in EU/EEMEA. Prior to joining MSD, he held line management roles in Sandoz and AstraZeneca.
Mr. Knox will be in charge of the global go-to-market strategy for a novel solution for pediatric anesthesiology, recently acquired from Advicenne. He has previous experience with the launch of Diprivan (propofol) in the UK and emerging markets.
In February 2016, Primex Pharmaceuticals acquired the global rights for an advanced oral pharmaceutical candidate for pediatric anesthesiology. With this acquisition, Primex Pharmaceuticals expanded its portfolio with a unique product whose market potential is evaluated as hundreds of millions of euros.
Panu Paappanen, Chairman of the Board and Owner,commented: “2016 could mark a milestone for Primex Pharmaceuticals. By strengthening our organization, we secure the in-house expertise needed to realize the full potential of our acquisition and build our anesthesia pipeline.”
Kari Sarvanto, President and Co-Founder of Primex Group,added: “I am excited to welcome a highly experienced colleague to our team to bring the new, patient-friendly solution to the market. We are committed to making Primex Pharmaceuticals the leading global anesthesia pharmaceutical company.”
About Primex Pharmaceuticals
Primex Pharmaceuticals is a fast growing global specialty company spearheading a new lean pharmaceutical business model.
Primex aims to become the leading global innovative Anesthesia company helping patients undergo a wide range of medical procedures. With a portfolio of strong, trusted anesthesia products including Recofol N (propofol) acquired from Bayer, and the recent acquisition of a novel, oral solution pharmaceutical candidate for pediatric anesthesiology from Advicenne, Primex Pharmaceuticals will continue to identify and acquire new medications that complete the ‘Triad of Anesthesia’.
Primex Pharmaceuticals’ global partner network operates in over 40 countries and reaches a population of one billion. The company is headquartered in Zug, Switzerland; all Primex products are manufactured in the EU. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.
More at www.Primexpharma.com